All News

sheila Tweet
RHEUMarampa
#mskus findings in pt w/normal muscle volume(ABC) vs. w/sarcopenia(DEF). This Japanese study showed US of VL muscle is useful in discriminating RA pts w & w/o sarcopenia. @RheumNow #ACR20 abs1537 https://t.co/Gv7V0eebEt
Olga Petryna Tweet
DrPetryna
@rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i
Eric Dein Tweet
ejdein1
Abst#1720: Interesting results in predicting +CCP progression to IA: high BMI ⬆️ risk, EtOH ⬇️ risk, Cigarettes no effect but low smoking group. #ACR20 @RheumNow.
Olga Petryna Tweet
DrPetryna
@rheumNow #ACR20 #ABSL02 registry data: Pts on biologics more likely to Shield at Home during COVID 19 as opposed to non-biologic or no systemic Rx at all. Such stringent mitigation tactics may contribute to the reported lower risk of adverse COVID-19 outcomes in biologics Pts
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
Retrosp study in France compared MRIs of 96 pts w/ SpA (65% w/ IBP) vs 104 w/o (25% w/ IBP): - 65% of pts w/ SpA had bone marrow edema (BME) mainly in the iliac quad of intermed middle segment - 20% w/o SpA had BME mainly in antero-middle quad. #Abst1535 #ACR2020 @RheumNow https://t.co/1ptGGUbUS4
Eric Dein Tweet
ejdein1
~1/3 early RA patients report unacceptable pain w/in one year of diagnosis. 69% have pain w/ low inflammation. No objective baseline measures predict unacceptable pain. #ACR20 @RheumNow Abs#1716 We need to start pain approaches at time of diagnosis for all
sheila Tweet
RHEUMarampa
How often do you perform NFC in suspected SSc patients? @RheumNow #ACR20
Wendy Costello Tweet
wendycostello2
@uptoTate @RheumNow It is only when I started working more closely with our rheum team to look at improving services did I realise how high no-shows are ! We have a 2yr waiting list so these appts are like gold dust. Unfortunately telemedicine not a viable option for your 1st rheum appt.
Eric Dein Tweet
ejdein1
Pulmonary disease and glucocorticoid usage risk factors for RA medication changes in first 3 month of #COVID19. Pts with higher reported disease activity more likely to make Rx changes #ACR20 @RheumNow. Abst#L05.
Sole Tweet
RetamozoSole
Frequency and Anatomic Distribution of MRI Lesions in the Sacroiliac Joints of Healthy Subjects and Patients with Spondyloarthritis. Dr Hecquet. #ACR20 @RheumNow BME was seen in 65% patients with Spa and in 20% without spondyloarthritis predominantly in the antero-middle quadrant https://t.co/OUYz2FQ5Yp
sheila Tweet
RHEUMarampa
Accdg to this study, no association was found between IFN levels and cognitive function in SLE pts (even after considering factors like SLE dse duration) Interesting! @RheumNow #ACR20 abs1788 @ZahiTouma https://t.co/F4j8H1CWJ9
Eric Dein Tweet
ejdein1
Important work by Dr. Winthrop on influenza AEs in Tofacinitib patients - similar among 5mg/10mg BID, only 2 deaths/~500 cases, both with H1N1 and co-morbid RFs. Abst#L04 @RheumNow #ACR20 https://t.co/7MZYGv8W3i
David Liew Tweet
drdavidliew
My axSpA patients often ask me whether whether it's the weight loss that matters, or just exercise. Some answers from @rheum_cat - BMI itself does matter in AS. Another one chalked up for the obesity-related inflammasome! #ACR20 ABST1883 @RheumNow https://t.co/oMOqA8ypTt
Eric Dein Tweet
ejdein1
Encouraging results on selective TK2 inhibitor in active PsA patients. ACR20 at week 16 of 53% and 63%, for low and high dose, compared to 32% placebo. NP, sinusitis, ha, rash most common AEs. Abst#L03 @RheumNow #ACR20 https://t.co/2UrOKFfnCL
Eric Dein Tweet
ejdein1
Evidence that patients on biologics getting COVID less frequently should be interpreted with the knowledge that Abst#L02 shows increased shielding/risk mitigation of patients on biologics #ACR20 @RheumNow https://t.co/Dn1lUtd6hl
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×